Gracell Biotechnologies : Corporate Presentation - August 2022

Gracell Biotechnologies

Pioneering the Next Generation of CAR-T Cell Therapies

Corporate Presentation | AUGUST 2022

NASDAQ:GRCL I gracellbio.com

Disclaimer

This presentation has been prepared by Gracell Biotechnologies Inc. (the "Company") solely for information purpose and has not been independently verified. By viewing or accessing the information contained in this presentation, the recipient hereby acknowledges and agrees that no representations, warranties or undertakings, express or implied, are made by the Company or any of its directors, shareholders, employees, agents, affiliates, advisors or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness or correctness of the information or opinions presented or contained in this presentation. None of the Company or any of its directors, shareholders, employees, agents, affiliates, advisors or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation. The information presented or contained in this presentation speaks as of the date of this presentation and is subject to change without notice.

Certain statements in this presentation, and other statements that the Company may make, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934, as amended., or the Private Securities Litigation Reform Act of 1995. These statements reflect the Company's intent, beliefs or current expectations about the future. These statements can be recognized by the use of words such as "expects," "plans," "will," "estimates," "projects," "intends," "anticipates," "believes," "confident" or words of similar meaning. These forward-looking statements are not guarantees of future performance and are based on a number of assumptions about the Company's operations and other factors, many of which are beyond the Company's control, and accordingly, actual results may differ materially from these forward-looking statements. The Company or any of its affiliates, advisers or representatives has no obligation and does not undertake to revise forward-looking statements to reflect future events or circumstances.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No securities of the Company may be sold in the United States without registration with the United States Securities and Exchange Commission (the "SEC") or an exemption from such registration pursuant to the Securities Act and the rules and regulations thereunder. No part of this presentation shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Specifically, these materials do not constitute a "prospectus" within the meaning of the Securities Act. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company and is qualified in its entirety by reference to those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the SEC.

2

Investment Highlights

Proprietary Cell Therapy Platforms

• FasTCAR - Next-day manufacturing, a gamer-changer for autologous CAR-T
• TruUCAR - Novel, elegant design to enable off-the-shelf allogeneic CAR-T

Rich Pipeline of Breakthrough CAR-T Candidates

• Five clinical stage candidates
  o Two China IND studies and three IIT studies
  o Two product candidates in three indications presented at ASCO and EHA 2022 o Plan to file INDs in U.S. and China
• Five preclinical candidates
  o In both hematological cancers and solid tumors

Strong Financial Position to Fund R&D Pipeline

• Cash position of $267.3 million as of 3/31/2022 o Well-fundedwith cash runway into 2024

3

Experienced Leadership Team

William Cao, Ph.D., B.M.

Founder, Chairman & CEO

• 30+ years of biotech and R&D experience
• Co-founderand former CEO of Cellular BiomedicinepiGroup
• 80+ issued patents & applications for advanced cell therapies

Wendy Li, M.D.

Chief Medical Officer

• 20+ years of experience leading all critical aspects of clinical development and medical affairs
• Over 30 successful IND, NDA and BLA filings

Kevin Xie, Ph.D., M.B.A.

Chief Financial Officer

• 20+ years of experience in healthcare investment and corporate leadership
• President and global portfolio manager of Fosun Healthcare Holdings

Samuel Zhang, Ph.D.

Chief Business Officer

• 20+ years of experience in business development, corporate strategy, and pharmaceutical commercialization
• CBO of NeoImmuneTech

Jenny Ni, M.D., Ph.D.

Chief Technology Officer

• 25+ years of experience in gene & cell therapy, vaccine and contract manufacturing
• Led CMC development of five IND filings / approvals for hematological and solid malignancies

4

Proprietary Technology Platforms and Enhancements

Technology platforms to improve treatment outcomes & overcome industry commercial bottlenecks

Autologous CAR-T Platform	Allogeneic CAR-T Platform
•	Next-day manufacturing	•	Off-the-shelf availability
• Younger T cells with enhanced fitness	•	Novel dual-directed CAR design to eliminate HvG
•	Fully-closed manufacturing capabilities		without need for extra immunosuppressive therapeutics

Proprietary

technology toolkit to enhance platforms

Dual CAR

• Deep expertise in protein chemistry
• True dual-antigen targeting
• Leveraging a second CAR to reduce rejection

SMART CARTTM

2nd Gen Enhanced CAR for Solid tumors

• To overcome and take advantage of immunosuppressive tumor microenvironment
• Enhanced CAR-T cell proliferation and killing activities
• Resisting exhaustion with improved persistence of CAR-T cells

5